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Abstract  
A number of human genetic polymorphisms are prevalent in tropical populations and appear to 
offer protection against symptomatic and/or severe malaria. We compared the prevalence of 
four polymorphisms, the sickle hemoglobin mutation (β globin E6V), the α-thalassemia 3.7 kb 
deletion, glucose-6-phosphate dehydrogenase deficiency caused by the common African 
variant (G6PD A-), and the CD36 T188G mutation in 1,344 individuals residing in districts in 
eastern (Tororo), south-central (Jinja), and southwestern (Kanungu) Uganda. Genes of interest 
were amplified, amplicons subjected to mutation-specific restriction endonuclease digestion (for 
sickle hemoglobin, G6PD A-, and CD36 T188G), reaction products resolved by electrophoresis, 
and genotypes determined based on the sizes of reaction products. Mutant genotypes were 
common, with many more heterozygous than homozygous alleles identified. The prevalences 
(heterozygotes plus homozygotes) of sickle hemoglobin (28% Tororo, 25% Jinja, 7% Kanungu), 
α-thalassemia (53% Tororo, 45% Jinja, 18% Kanungu) and G6PD A- (29% Tororo, 18% Jinja, 
8% Kanungu) were significantly greater in Tororo and Jinja compared to Kanungu (p<0.0001 for 
all three alleles); prevalences were also significantly greater in Tororo compared to Jinja for α-
thalassemia (p = 0.03) and G6PD A- (p<0.0001). For the CD36 T188G mutation, the prevalence 
was significantly greater in Tororo compared to Jinja or Kanungu (27% Tororo, 17% Jinja, 18% 
Kanungu; p = 0.0004 and 0.0017, respectively). Considering ethnicity of study subjects, based 
on primary language spoken, the prevalence of mutant genotypes was lower in Bantu compared 
to non-Bantu language speakers, but in the Jinja cohort, the only study population with a 
marked diversity of language groups, prevalence did not differ between Bantu and non-Bantu 
speakers. These results indicate marked differences in human genetic features between 
populations in different regions of Uganda. These differences might be explained by both ethnic 
variation and by varied malaria risk in different regions of Uganda.   
 
Keywords: Malaria, Plasmodium, Sickle, Thalassemia, G6PD, CD36 
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1. Introduction 
 Multiple human genetic polymorphisms are prevalent in tropical populations and offer 
protection against malaria, suggesting that these were selected in human populations due to 
protection against death from Plasmodium falciparum infection (Hedrick, 2011). As first 
proposed by Haldane, disadvantages of a homozygous mutation can be balanced by 
advantages to heterozygotes in protection against infectious diseases (Haldane, 1949).  It has 
been suggested that malaria has offered the strongest evolutionary pressure of any infectious 
disease in recent human history (Kwiatkowski, 2005), and disorders of erythrocytes are the 
most common genetic disorders of humans (Weatherall, 2008). 
Strong evidence supports balanced polymorphisms for sickle cell disease, α-
thalassemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, all of which are 
deleterious primarily in homozygotes, but appear to offer protection against severe malaria in 
heterozygotes, and are most prevalent in populations currently or historically at high risk of 
mortality from falciparum malaria (Kwiatkowski, 2005; Taylor and Fairhurst, 2014; Verra et al., 
2009; Williams, 2006). The sickle hemoglobin mutation (β globin E6V) has a frequency of up to 
about 20% in populations in Africa, southern Europe, and India, and in multiple case-control 
studies the heterozygous AS genotype has been associated with over 70% protection against 
severe malaria (Kwiatkowski, 2005; Verra et al., 2009). α-thalassemia, due to deletion of one or 
more linked β globin genes, is very common in many tropical populations; the common variant 
in Africa contains a 3.7 kb deletion (Hedrick, 2011). α-thalassemia has been associated with 
marked protection against severe malaria in multiple studies from Africa (May et al., 2007; 
Williams et al., 2005) and elsewhere (Allen et al., 1997). G6PD deficiency is the most common 
enzyme deficiency in humans (Nkhoma et al., 2009). The common G6PD deficiency genotype 
in African populations is G6PD A- (V68M and N126D), which leads to an enzyme deficiency that 
is marked, but not as severe as with some other genetic variants (Town et al., 1992). G6PD A- 
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has been associated with protection against severe malaria in African populations (Guindo et 
al., 2007; Ruwende et al., 1995), although associations for this polymorphism have been less 
consistent than for sickle hemoglobin and α-thalassemia (Verra et al., 2009). 
The human CD36 antigen is an integral membrane protein in many cell types and a 
member of the scavenger receptor family that imports fatty acids into cells (Canton et al., 2013). 
CD36 is also an endothelial receptor for binding of erythrocytes infected with P. falciparum; this 
cytoadhesion is believed to be an important feature of the virulence of falciparum malaria, due 
both to its prevention of clearance of infected erythrocytes by the spleen and to local effects of 
cytoadhering parasites (Newbold et al., 1999). Importantly, expression of CD36 is low in the 
brain, even in the setting of cerebral malaria (Silamut et al., 1999), suggesting that binding to 
CD36 is most relevant in non-cerebral forms of severe malaria. CD36 is also believed to be an 
important macrophage pattern recognition receptor that mediates innate recognition and 
clearance of infected erythrocytes (Cabrera et al., 2014). Considering our current 
understanding, CD36 expression might be seen to contribute to malaria severity, by mediating 
cytoadherence, or to help control malaria, via immune effects. Results with murine malaria 
models have been complex; mice with decreased CD36-mediated cytoadherence had 
decreased growth of P. berghei (Fonager et al., 2012), but CD36-deficient mice had increased 
risk of fatal P. chabaudi malaria (Patel et al., 2007). Considering human populations, many 
CD36 polymorphisms, including nonsense mutations that prevent expression of the protein, are 
common, particularly in African populations (Aitman et al., 2000). However, attempts to identify 
associations between common polymorphisms and malaria risk have led to inconsistent results, 
with evidence for enhancement of (Aitman et al., 2000; Omi et al., 2002), no effect (Fry et al., 
2009), or protection from (Das et al., 2009; Omi et al., 2003; Pain et al., 2001; Sinha et al., 
2008) severe malaria with different polymorphisms.  
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 High prevalence of malaria-protective genetic polymorphisms is clearly associated with 
malaria endemicity, but prevalence varies among populations in endemic areas. Some of this 
difference can be explained by local malaria risk, as suggested by decreased prevalence of  
protective polymorphisms with increasing altitude in endemic countries (Hedrick, 2011). The 
prevalence of some protective polymorphisms has also been shown to vary between ethnic 
groups. In West Africa, the Fulani ethnic group has decreased susceptibility to malaria 
compared to Dogon populations (Bereczky et al., 2006), and the Fulani also have decreased 
prevalence of sickle hemoglobin (Nasr et al., 2008), α-thalassemia (Modiano et al., 2001a), and 
G6PD A- (Maiga et al., 2014; Modiano et al., 2001a) compared to other groups. In this case 
decreased malaria is likely not explained by genetic polymorphisms, but rather selective 
pressure for the balanced polymorphisms may have been lower in the Fulani due to decreased 
malaria incidence. In order to characterize the prevalence of key malaria-protective 
polymorphisms in Uganda, where malaria risk varies between regions of the country and ethnic 
diversity is great, we characterized polymorphisms in residents of three regions of the country.  
 
2. Materials and methods 
2.1. Study populations.  
Cohorts were enrolled in three regions of Uganda (Kamya et al., 2015). The study sites 
were Nagongera Sub-county, Tororo District, a rural area with high transmission intensity in 
southeastern Uganda near the Kenyan border; Walukuba Sub-county, a peri-urban area near 
the city of Jinja and adjoining Lake Victoria in south-central Uganda; and Kihihi Sub-county, 
Kanungu District, a rural area with moderate transmission intensity in southwestern Uganda 
(Figure 1). To establish the cohorts, all households within the three sub-counties were 
enumerated and mapped, and randomly selected households that included at least one resident 
0.5-10 years of age and one adult resident were enrolled, as previously described (Kamya et al., 
2015). This study included cohort members reported previously and additional subjects 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
6 
 
recruited into the cohorts after prior reports (Kamya et al., 2015; Rek et al., 2016). Cohort 
household adults provided the primary language spoken by the household. All cohort subjects 
provided a blood sample for genetic analysis. The parent cohort study and the genetic 
evaluations described in this report were approved by the Makerere University Research and 
Ethics Committee, the Uganda National Council for Science and Technology, and the University 
of California, San Francisco Committee on Human Research.  
 
2.2. Laboratory reagents.  
All PCR and restriction endonuclease reagents were from New England Biolabs, except 
as noted. Other reagents were from Sigma-Aldrich, or as noted. Molecular grade water was 
used in all reactions. 
 
2.3. Sample collection and DNA purification.  
Blood samples were collected into EDTA tubes, and DNA was purified from buffy coats 
using QIAamp DNA Mini Kits (Qiagen), following manufacturer’s instructions with minor 
modifications. For each sample 300 μl of buffy coat was mixed with 20 μl of kit protease enzyme 
solution and then 200 μl of lysis buffer, the mixture was vortexed for 15 sec and incubated at 
56°C for 10 min, and then 200 μl of absolute ethanol was added. The mixture was vortexed 
briefly and transferred to a QIAamp column, and the column was spun for 1 min at 8000 rpm. 
The column was then washed twice with wash buffer, and DNA was eluted by incubating with 
80 μl of elution buffer at room temperature for 5 min followed by centrifugation at 8,000 rpm for 
5 min.  
 
2.4. Characterization of sickle hemoglobin.  
As previously described (Modiano et al., 2001b), 2 μl of purified DNA was amplified in a 
50 μL reaction consisting of 5 μl of PCR 10X Taq buffer, 1.0 μl each of 10 μM forward (5’-
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AGGAGCAGGGAGGGCAGG A -3’) and reverse (5’-TCCAAGGGTAGACCACCAGC-3’) 
primers, 5 μL of each dNTP (2 mM), and 0.2 μl Taq DNA polymerase (5 U/μL). PCR conditions 
were 96°C for 5 min followed by 30 cycles of 96°C for 30 sec, 60°C for 1 min, and 72°C for 30 
sec, followed by 72°C for 10 min. 15 μl of the PCR product was digested by incubating at 37°C 
for 3 h with 2 μL10X CutSmart buffer, 0.2 μL BSA, 1 μL MnlI (5 U/μL) or 0.5 μL DdeI (10 U/μL) 
endonuclease, and 1.8 μL water. All PCR reactions described in this report included positive 
and negative controls. Reaction products were resolved in 3% agarose gels and stained with 
ethidium bromide, and sizes were determined based on DNA ladders. Expected fragment sizes 
were, for MnII reactions: HbAA: 173 bp, 109 bp, and 60 bp; HbCC/SS/SC: 173 bp, 109 bp, and 
76 bp; HbAC/AS: 173 bp, 109 bp, 76bp, and 60 bp; and for DdeI reactions:  HbSS: 331 bp; 
HbSC: 130 bp, 201 bp, and 331 bp; HbCC: 201 bp and 130 bp; HbAS: 130bp, 201bp, and 
331bp; HbAC: 130 bp and 201 bp.  
 
2.5. Characterization of α-thalassemia 3.7 kb deletion.  
As previously described (Liu et al., 2000), 1.5 ul of purified DNA was amplified in a 25 μl 
reaction consisting of 12.5 μl HotStart Taq DNA polymerase mix containing dNTPs (Qiagen), 
0.5 μl forward primer (5’-AAGTCCACCCCTTCCTTCCTCACC-3’), 0.2 μl reverse primer 1 (5’-
ATGAGAGAAATGTTCTGGCACCTGCACTTG-3’), 0.2 μl reverse primer 2 (5’-
TCCATCCCCTCCTCCCGCCCCTGCCTTTTC-3’; each primer 25 μM), 1.25 μl DMSO, and 3.75 
μl glycine betaine (5 M). PCR conditions were 95°C for 16 min, followed by 35 cycles of 95°C 
for 60 sec, 62°C for 60 sec, 72°C for 150 sec, followed by 72°C for 10 min. Amplicons were 
resolved in 1% agarose gels and stained with ethidium bromide. Wild type (αα/αα) contained a 
single 2,213 bp product, heterozygotes (carriers, αα/-α3.7) products of 2,213 bp and 1,963 bp, 
and homozygotes (-α3.7/-α3.7) a 1,963 bp product.  
 
2.6. Characterization of G6PD A-.  
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As previously described (Fanello et al., 2008), 2 μL of purified DNA was amplified in a 30 
μL reaction containing 3 μl of 10X Taq buffer, 1 μL each of 10 μM forward (5’-
CTGGCCAAGAAGAAG ATCTACCC-3’) and reverse (5’-GAGAAAACGCAGCAGAGCACAG 3’) 
primers, 3 μl of each dNTP (2 mM), and 0.2 μl Taq DNA polymerase (5 U/μL). PCR conditions 
were 95°C for 5 min, followed by 30 cycles of 95°C for 40 sec, 64°C for 40 sec, and 72°C for 40 
sec, followed by 72°C for 10 min. 15 μl of the PCR product was digested by incubating at 37°C 
for 3 h with 2 μl 10X CutSmart buffer, 0.2 μl BSA, 0.3 μl NlaIII (10 U/uL), and 2.5 μL water. 
Reaction products were resolved in 2.5% agarose gels and stained with ethidium bromide. Wild 
type contained fragments of 300 bp and 150 bp; heterozygotes fragments of 300 bp, 150 bp, 
and 140 bp; and homozygotes (and hemizygous males) fragments of 150 bp and 140 bp. 
 
2.7. Characterization of CD36 T188G.  
As previously described (Das et al., 2009), 2 µl of purified DNA was amplified in a 50 μL 
reaction with 5 μl of 10X Taq buffer, 1 μL each  of 10 μM forward (5’-
CTATGCTGTATTTGAATCCGACGTT-3’) and reverse (5’-CTGTGCTACTGAGGTTATTTACTC-
3’) primers, 5 μl of each dNTP (2 mM), and 0.2 μl Taq DNA polymerase (5 U/μL). PCR 
conditions were 95°C for 3 min, followed by 40 cycles of 95°C for 30 sec, 55°C for 30 sec, and 
72°C for 1 min, followed by 72°C for 10 min. 15 μl of the PCR product was digested by 
incubating at 37°C for 5 h with 3 μl 10X CutSmart buffer, 1 μl NdeI (10 U/uL), and 11 μL water. 
Reaction products were resolved in 2% agarose and stained with ethidium bromide. Wild type 
contained fragments of 148 bp and 64 bp; heterozygotes fragments of 212 bp, 148 bp, and 64 
bp; and mutants a single 212 bp fragment. 
 
2.8. Data analysis.  
Outcomes for each tested genotype were categorized as wild type, heterozygous, or 
homozygous. For α-thalassemia the αα/αα genotype represents wild type, αα/-α3.7 the 
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heterozygote (silent carrier), and -α3.7/-α3.7 the homozygous mutation. For G6PD A-, 
homozygous females and hemizygous males were considered homozygotes. Prevalences of 
polymorphisms were compared using the Fisher’s exact test, with comparisons either between 
wild type and heterozygotes/homozygotes combined or between wild type and only 
heterozygotes. P-values <0.05 were considered statistically significant. 
 
3. Results 
3.1. Study sites and populations.  
Study populations were members of cohorts enrolled from a rural area of Tororo District 
in southeastern Uganda; a peri-urban area of Jinja District, in south-central Uganda; and a rural 
area of Kanungu District in southwestern Uganda (Figure 1; Table 1). Out of the 1,344 subjects 
enrolled, 44% were children under 5 years of age, 32% 5-10 years, and 24% above 18 years. 
Prior reports defined malaria transmission, prevalence, and incidence in the three cohorts, as 
summarized in Table 1 (Kamya et al., 2015; Rek et al., 2016). The sites differed markedly, with 
very high transmission intensity, parasite prevalence, and malaria incidence in Tororo District, 
lower levels of all of these parameters in Kanungu District, and the lowest levels in Jinja District. 
Of note, malaria transmission was considerably greater in earlier surveys of Jinja District, and 
transmission has since decreased greatly in Tororo District after a campaign of indoor residual 
spraying of insecticide that was launched in 2014 (Katureebe et al., 2016). Historically, it 
appears that malaria transmission intensity followed the rank order Tororo > Jinja > Kanungu 
(Yeka et al., 2012).  It is anticipated that various differences between study sites impact on 
malaria transmission intensity; our goal in this study was to compare human genetic 
polymorphisms that may have been selected under differential malaria selection pressures at 
the sites.  
 
3.2. Comparative prevalence of human genetic polymorphisms at three sites in Uganda.  
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DNA from cohort subjects was analyzed for the prevalence of four polymorphisms 
associated with protection against malaria: the sickle hemoglobin mutation (β globin E6V), α-
thalassemia, G6PD deficiency caused by the common African variant (G6PD A-; V68M and 
N126D), and the CD36 T188G mutation (which introduces a stop codon in exon 10). For all 
studied sites and alleles, >95% of samples were successfully analyzed. For all of these 
polymorphisms, mutant genotypes were common, with many more heterozygous than 
homozygous alleles identified (Table 2). HbC (β globin E6K) was not identified in any samples. 
Marked differences were identified in prevalences of polymorphisms of interest at the three 
study sites. For sickle hemoglobin, α-thalassemia, and G6PD deficiency, prevalences of wild 
type were lowest in Tororo and highest in Kanungu; for CD36 T188G prevalence of wild type 
was lowest in Tororo, and the same in Jinja and Kanungu (Table 3; Figure 2). Consideration of 
any two polymorphisms together yielded associations similar to those seen for individual 
polymorphisms, with prevalences of wild type generally lowest in Tororo and highest in Kanungu 
(Supplemental Table 1). 
 
3.3. Comparative prevalence of human genetic polymorphisms among different ethnic groups.  
 Uganda has a highly diverse population, and it was of interest to determine if differences 
in the prevalences of genetic polymorphisms were associated with the ethnicity of different 
populations. Ethnicity was defined based on the primary language spoken by the household, 
with stratification for speakers of Bantu and non-Bantu (Nilotic and Central Sudanic) languages. 
Each study population included a range of ethnicities, but the Tororo cohort was primarily 
composed of speakers of Dhopadhola, a Nilotic language; the Jinja cohort included a mixture of 
Bantu and non-Bantu speakers, and the Kanungu cohort contained nearly all Bantu speakers 
(primarily Bakiga and Banyarwanda; Supplemental Table 2). The four studied polymorphisms 
were all more common in non-Bantu speakers, with differences in prevalence statistically 
significant for all but the CD36 T188G mutation (Table 3). This result suggests that differences 
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in prevalence between Ugandan sites were largely explained by major ethnic differences among 
the study populations. However, when prevalences were compared among ethnic groups in 
Jinja, the only site with large numbers of both Bantu and non-Bantu speakers, no differences in 
prevalence of any of the studied polymorphisms were seen between Bantu and non-Bantu 
speakers (Supplemental Table 3). Thus, both ethnicity and place of residence appear to have 
contributed to the observed differences in prevalence of studied traits. 
 
4. Discussion 
 We characterized the prevalences of four common human genetic polymorphisms, each 
previously associated with protection against severe malaria, in three regions of Uganda. All 
four polymorphisms demonstrated similar patterns, with highest prevalence in Tororo District, in 
eastern Uganda and, except for CD36 T188G, lowest prevalence in Kanungu District, in 
southwestern Uganda. Considering ethnicity of study populations, prevalence of the 
polymorphisms was greatest among non-Bantu speakers. However, in Jinja District, the only 
site with a highly diverse ethnic make-up, prevalence of the polymorphisms was not associated 
with ethnicity. Our results indicate marked variations in the prevalences of malaria-protective 
human genetic polymorphisms between populations in different regions of Uganda and suggest 
that these variations might be explained both by ethnic differences and by varied malaria risk in 
different regions of the country.    
 The three Ugandan study sites differed greatly in recent malaria transmission intensity 
(Kamya et al., 2015; Katureebe et al., 2016). Tororo District has had very high transmission 
intensity recorded, with entomologic inoculation rates >300 infectious bites per year, although 
very recently transmission intensity has decreased due to an intensive IRS campaign. Jinja 
District has had decreasing transmission intensity, presumably due to both improved utilization 
of ITNs and malaria case management, and to effects of urbanization. Kanungu District has 
intermediate levels of malaria transmission intensity. However, appreciation of malaria 
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transmission prior to recent intensive control efforts and urbanization suggests that the rank 
order for historical transmission intensity for these sites is Tororo > Jinja > Kanungu (Yeka et al., 
2012). Thus, our measured prevalences of genetic polymorphisms followed a pattern similar to 
that of historical malaria transmission intensity, with the prevalence of all four studied 
polymorphisms highest in Tororo, the region with the highest transmission intensity, potentially 
explained by the greatest selective pressure for mutations that protect against lethal malaria at 
this site.  
 Our study also collected information on the primary language of study households, a 
proxy for ethnicity, and thus it offered the opportunity to assess associations between ethnicity 
and genetic polymorphisms. A large literature has demonstrated that, in studies across 
populations, linguistic trees correspond remarkably well to genetic trees (Cavalli-Sforza, 1997).  
In our case, there were strong associations between language and genetic polymorphisms. The 
prevalence of sickle hemoglobin, a-thalassemia, and G6PD deficiency were all greatest in non-
Bantu speakers. Major movements of different African populations appear to have occurred 
over about the last 3,000-8,000 years (Beltrame et al., 2016). Our results suggest that non-
Bantu speakers, in our study consisting of speakers of Nilotic and Central Sudanic languages, 
whom appear to have originated from the area of modern Sudan and South Sudan, experienced 
greater malaria risk than did Bantu-speaking groups, who are believed to have originated 
around modern Cameroon and Nigeria (Beltrame et al., 2016). A number of dating studies 
suggest that sickle hemoglobin and G6PD deficiency  arose within the last few thousand years 
(Hedrick, 2011). The marked differences in prevalences of malaria-protective polymorphisms 
between ethnic groups are consistent with our recent understanding of the evolution of P. 
falciparum, with the appreciation that this parasite crossed from gorillas to humans quite 
recently, probably within the last 10,000 years (Loy et al., 2017). Thus, it is plausible that 
modern differences in the prevalence of malaria-protective human genetic polymorphisms are 
due to differences in malaria risk over the last few thousand years.  
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 In summary, we identified marked variation in the prevalences of human genetic 
polymorphisms in residents of three different regions of Uganda. These differences may be due, 
in part, to differences in historical malaria risk between these regions and to genetic differences 
between the ethnic groups principally inhabiting these regions. The large differences in 
prevalences of balanced polymorphisms between harmful homozygous and protective 
heterozygous mutations suggest a profound impact of fatal falciparum malaria on the human 
genome. 
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Figure legends  
Figure 1. Study sites. Districts and subcounties are labelled and shaded in gray and black, 
respectively. 
 
Figure 2. Prevalence of studied polymorphisms at the three study sites.   
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Table 1. Description of study sites. 
 
1
The cohorts consisted of children up to 11 years of age and adults over 18 years of age.  
2
These results are from Kamya et al., 2015. 
 
 
 
 
Table 2. Overall prevalence (%) of human genetic polymorphisms at 3 sites in Uganda. 
Polymorphism N Wild type Heterozygous Homozygous 
HbS 1,321 1,060 (80.2) 256 (19.4) 5 (0.4) 
α-Thalassemia 1,284 794 (61.8) 420 (32.7) 70 (5.5) 
G6PD deficiency 1,323 1,083 (81.9) 166 (12.5) 74 (5.6) 
CD36 T188G 1,334 1,061 (79.5) 263 (19.7) 10 (0.7) 
 
 
  
 Study site 
Characteristics of sites Tororo Jinja Kanungu 
     Location Southeastern South-central Southwestern 
     Setting Rural Peri-urban Rural 
     Altitude  695-1,443 m 1,102-1,500 m 886-1,329 m 
Number of study subjects
1
    
     Children 340 321 365 
      Adults 106 114 98 
     Total 446 435 463 
Malaria indicators (children)
2
    
     Entomological inoculation rate per year 310 2.8 32.0 
     Parasite prevalence 28.7% 7.4% 9.3% 
     Malaria incidence per year 2.81 0.43 1.43 
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Table 3. Comparative prevalence (%) of polymorphisms of interest at 3 sites in Uganda. 
Site Polymorphism P-value
1
 
 N WT Heterozy
gous 
Homozygous T vs. J T vs. K J vs. K 
 HbS    
Tororo 434 313 (72) 119 (27) 2 (1) 0.442  
<0.0001 
 
 
<0.0001 
Jinja 429 320 (75) 106 (24) 3 (1) 
Kanungu 458 427 (93) 31 (7) 0 
 
 α-Thalassemia    
Tororo 414 196 (47) 190 (46) 28 (7) 0.0327  
<0.0001 
 
 
<0.0001 
Jinja 430 236 (55) 156 (37) 38 (8) 
Kanungu 440 362 (82) 74 (17) 4 (1) 
 
 G6PD deficiency    
Tororo 438 310 (71) 80 (18) 48 (11) <0.0001  
<0.0001 
 
 
<0.0001 
Jinja 432 355 (82) 58 (14) 19 (4) 
Kanungu 453 418 (92) 28 (6) 7 (2) 
 
 CD36 T188G    
Tororo 442 324 (73) 114 (26) 4 (1) 0.0004  
0.0017 
 
 
0.724 
Jinja 433 360 (83) 67 (16) 6 (1) 
Kanungu 459 377 (82) 82 (18) 0 
 
1
P-values for comparisons of prevalences in Tororo (T), Jinja (J), and Kanungu (K) Districts were 
determined for comparisons of wild type (WT) vs. heterozygous + homozygous genotypes using the 
Fisher’s exact test. Consideration of WT vs. only heterozygous genotypes identified the same 
comparisons as statistically significant.  
 
 
Table 4. Comparative prevalence (%) of polymorphisms in Bantu and non-Bantu 
language speakers. 
Language Polymorphism P-value
1
 
 N WT Heterozygous Homozygous  
 HbS  
Bantu 692 595 (86.0) 96 (13.9) 1 (0.1) <0.0001 
Non-Bantu 472 358 (75.8) 109 (23.1) 5 (1.1) 
 
 α-Thalassemia  
Bantu 676 487 (72.0) 169 (25.0) 20 (3.0) <0.0001 
Non-Bantu 461 230 (49.9) 196 (42.5) 35 (7.6) 
 
 G6PD deficiency  
Bantu 689 606 (87.1) 65 (9.4) 18 (2.6) <0.0001 
Non-Bantu 464 342 (73.7) 79 (17.0) 43 (9.3) 
 
 CD36 T188G  
Bantu 652 542 (83.1) 106 (16.3) 4 (0.6) 0.094 
Non-Bantu 430 340 (79.1) 86 (20.0) 4 (0.9) 
 
1
P-values for comparisons of prevalences between language groups were determined for comparisons of 
wild type (WT) vs. heterozygous + homozygous genotypes using the Fisher’s exact test. Consideration of 
WT vs. only heterozygous genotypes identified the same comparisons as statistically significant. 
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Fig. 1 
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Fig. 2 
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Highlights for Review 
 
Prevalence of 4 malaria-protective human genetic polymorphisms varied across Uganda. 
Prevalence of mutations was lowest in southwestern Uganda. 
Prevalence of mutations was lower in Bantu compared to non-Bantu language speakers. 
Genetic differences might be explained by ethnic variation and varied malaria risk. 
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